Daniel Lietha

Daniel Lietha is a prominent researcher and Group Leader at the Centro de Investigaciones Biológicas (CIB-CSIC), a biological research center in Spain.12 His work focuses on cellular signaling and adhesion mechanisms, with particular emphasis on regulatory processes controlling growth and adhesion signals.1

Research Interests

Lietha's research group studies key signaling switches that regulate important cellular functions. Their work encompasses several areas:

1. Focal Adhesion Kinase (FAK): Lietha has conducted significant research on FAK activation and its role in cell adhesion.1

2. SARS-CoV-2 Interactions: His team has contributed to studies on SARS-CoV-2 and ACE2 interactions.1

3. Cancer Research: Lietha has been involved in studies related to cancer, including work on SRC inhibition for improved drug efficacy and tolerability in cancer treatment.1

4. Lipid Membranes and Cell Signaling: His research extends to the roles of membrane domains in integrin-mediated cell adhesion.1

Notable Publications

Lietha has authored numerous scientific papers in prestigious journals. Some of his recent publications include:

• A study on SARS-CoV-2 interactions published in Proceedings of the National Academy of Sciences (2022).1
• Research on SRC inhibition for cancer treatment in Cancer Research (2021).1
• A paper on the structural basis of Focal Adhesion Kinase activation on lipid membranes in EMBO Journal (2020).1

Funding and Collaborations

As a principal investigator, Lietha has secured multiple research grants from various organizations, including:

• MICINN (Spanish Ministry of Science and Innovation)
• Worldwide Cancer Research
• Volkswagen Foundation1

These grants indicate his standing in the scientific community and the relevance of his research.

Daniel Lietha's work at CIB-CSIC contributes significantly to our understanding of cellular processes and has potential implications for various fields, including cancer research and infectious diseases.